Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 3
1970 1
1976 2
1977 1
1978 1
1979 3
1981 3
1982 6
1983 6
1984 3
1985 9
1986 9
1987 9
1988 8
1989 9
1990 18
1991 16
1992 16
1993 10
1994 19
1995 24
1996 26
1997 17
1998 19
1999 20
2000 17
2001 28
2002 32
2003 26
2004 34
2005 31
2006 18
2007 20
2008 23
2009 20
2010 28
2011 35
2012 42
2013 35
2014 37
2015 40
2016 57
2017 58
2018 65
2019 47
2020 51
2021 70
2022 62
2023 72
2024 45

Text availability

Article attribute

Article type

Publication date

Search Results

1,128 results

Results by year

Filters applied: . Clear all
Page 1
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. Baas P, et al. Among authors: fujimoto n. Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21. Lancet. 2021. PMID: 33485464 Clinical Trial.
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. Peters S, et al. Among authors: fujimoto n. Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3. Ann Oncol. 2022. PMID: 35124183 Free article. Clinical Trial.
DOCK2 is involved in the host genetics and biology of severe COVID-19.
Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T, Okudela K, Okuzaki D, Motooka D, Kanai M, Naito T, Yamamoto K, Wang QS, Saiki R, Ishihara R, Matsubara Y, Hamamoto J, Hayashi H, Yoshimura Y, Tachikawa N, Yanagita E, Hyugaji T, Shimizu E, Katayama K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Aoki R, Nakamura A, Harada S, Sasano H, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagimoto S,… See abstract for full author list ➔ Namkoong H, et al. Among authors: fujimoto n. Nature. 2022 Sep;609(7928):754-760. doi: 10.1038/s41586-022-05163-5. Epub 2022 Aug 8. Nature. 2022. PMID: 35940203 Free PMC article.
Steroidogenesis in castration-resistant prostate cancer.
Shiota M, Endo S, Blas L, Fujimoto N, Eto M. Shiota M, et al. Among authors: fujimoto n. Urol Oncol. 2023 May;41(5):240-251. doi: 10.1016/j.urolonc.2022.10.018. Epub 2022 Nov 11. Urol Oncol. 2023. PMID: 36376200 Review.
Subtype of EGFR exon 19 deletion mutations.
Fujimoto N. Fujimoto N. Transl Lung Cancer Res. 2024 Jan 31;13(1):195-198. doi: 10.21037/tlcr-23-680. Epub 2024 Jan 17. Transl Lung Cancer Res. 2024. PMID: 38404992 Free PMC article. No abstract available.
The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force.
Wang QS, Edahiro R, Namkoong H, Hasegawa T, Shirai Y, Sonehara K, Tanaka H, Lee H, Saiki R, Hyugaji T, Shimizu E, Katayama K, Kanai M, Naito T, Sasa N, Yamamoto K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Ichikawa M, Nakamura A, Harada S, Sandhu Y, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagimoto S, Noguchi Y, Yamano Y, Sasano H, Ota S, Nakamori Y, Yoshiya K, Saito F, Yoshihara T, Wada D, Iwamura H, Kanayama S, Maruyama S, Yoshiyama T, Ohta K, Kok… See abstract for full author list ➔ Wang QS, et al. Among authors: fujimoto n. Nat Commun. 2022 Aug 22;13(1):4830. doi: 10.1038/s41467-022-32276-2. Nat Commun. 2022. PMID: 35995775 Free PMC article.
Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer.
Shiota M, Akamatsu S, Narita S, Terada N, Fujimoto N, Eto M. Shiota M, et al. Among authors: fujimoto n. JMA J. 2021 Apr 15;4(2):99-111. doi: 10.31662/jmaj.2021-0004. Epub 2021 Mar 26. JMA J. 2021. PMID: 33997443 Free PMC article. Review.
Erythema multiforme major induced by tramadol.
Yamada M, Furuta M, Fujimoto N. Yamada M, et al. Among authors: fujimoto n. Eur J Dermatol. 2023 Aug 1;33(4):437-439. doi: 10.1684/ejd.2023.4520. Eur J Dermatol. 2023. PMID: 37823501 No abstract available.
1,128 results